{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:26:39Z","timestamp":1793694399840,"version":"4.5.1"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,3,11]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, with increasing mortality rates driven by the obesity pandemic. Weight loss has been shown to improve MASLD outcomes, yet the effectiveness of eHealth interventions in MASLD management remains uncertain. We aimed to evaluate the effectiveness of eHealth interventions compared with standard care in improving health outcomes among patients with MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Relevant studies were retrieved from PubMed, Cochrane Central and Embase databases from inception to 26 April 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Only double-arm clinical trials involving human participants diagnosed with MASLD were included. Eligible studies were limited to those published in English.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>eHealth interventions\u2014including internet-based platforms, smartwatches, telephone follow-ups and mobile applications for dietary and exercise modifications\u2014were compared against traditional intervention methods. The primary outcomes assessed were changes in body weight, abdominal\/waist circumference, aspartate aminotransferase (AST) and alanine transaminase (ALT). Secondary outcomes were changes in body mass index (BMI), diastolic blood pressure, systolic blood pressure, MASLD fibrosis score, high-density lipoprotein, gamma-glutamyl transferase and triglycerides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>11 studies met the inclusion criteria, of which 10 provided relevant outcomes and were included. The mean age of participants across the studies ranged from 39.3 to 57.9 years, with intervention durations spanning 3 to 24 months. Our results indicate significant improvements with eHealth interventions compared with control comparators, including reductions in AST (standardised mean difference (SMD): \u22120.35 (95% CI \u20130.61, \u20130.10); p&lt;0.05), ALT (SMD: \u22120.38 (95% CI \u20130.65, \u20130.11); p&lt;0.05), weight loss (SMD: \u22120.38 (95% CI \u20130.60, \u20130.17); p&lt;0.05) and BMI (SMD: \u22120.37 (95% CI \u20130.54, \u20130.21); p&lt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The utilisation of eHealth interventions showed significant improvements in outcomes related to AST, ALT, abdominal circumference, weight loss and BMI. However, future studies with larger sample sizes and longer follow-ups are warranted to assess the sustainability of these outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2024-001670","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T20:50:17Z","timestamp":1744231817000},"page":"e001670","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["eHealth interventions and patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"given":"Yousuf","family":"Zafar","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Mississippi University Hospital, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umer","family":"Sohail","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9959-007X","authenticated-orcid":false,"given":"Syed Zaeem","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ovais","family":"Sohail","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Missouri, Columbia, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javaid","family":"Zafar","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi University Hospital, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Lirette","sequence":"additional","affiliation":[{"name":"Department of Data Science, University of Mississippi Medical Center, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Singal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Louisville School of Medicine; Trager Transplant Center and Jewish Hospital, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2026010701052021000_12.1.e001670.1","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026010701052021000_12.1.e001670.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0"},{"key":"2026010701052021000_12.1.e001670.3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"2026010701052021000_12.1.e001670.4","article-title":"Increasing nonalcoholic fatty liver disease-related mortality rates in the United States from 1999 to 2022","volume":"7","author":"Ilyas","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026010701052021000_12.1.e001670.5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00143-6"},{"key":"2026010701052021000_12.1.e001670.6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","article-title":"An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026010701052021000_12.1.e001670.7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22575"},{"key":"2026010701052021000_12.1.e001670.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912063"},{"key":"2026010701052021000_12.1.e001670.9","unstructured":"Weight loss results in significant improvements in quality o.: Hepatology, Available: https:\/\/journals.lww.com\/hep\/abstract\/2016\/04000\/weight_loss_results_in_significant_improvements_in.22.aspx [Accessed 26 Apr 2024]."},{"key":"2026010701052021000_12.1.e001670.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"2026010701052021000_12.1.e001670.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28392"},{"key":"2026010701052021000_12.1.e001670.12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1478-3231.2007.01567.x","article-title":"Treating nonalcoholic fatty liver disease","volume":"27","author":"M\u00e9ndez-S\u00e1nchez","year":"2007","journal-title":"Liver Int"},{"key":"2026010701052021000_12.1.e001670.13","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1007\/s10620-020-06673-w","article-title":"Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease","volume":"66","author":"Stine","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026010701052021000_12.1.e001670.14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/apt.15063","article-title":"Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease","volume":"49","author":"Konerman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026010701052021000_12.1.e001670.15","doi-asserted-by":"publisher","DOI":"10.1097\/JCN.0000000000000120"},{"key":"2026010701052021000_12.1.e001670.16","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.2283","article-title":"Adherence to a smartphone application for weight loss compared to website and paper diary: pilot randomized controlled trial","volume":"15","author":"Carter","year":"2013","journal-title":"J Med Internet Res"},{"key":"2026010701052021000_12.1.e001670.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.07.013"},{"key":"2026010701052021000_12.1.e001670.18","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000499","article-title":"Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","volume":"8","author":"Albhaisi","year":"2024","journal-title":"Hepatol Commun"},{"key":"2026010701052021000_12.1.e001670.19","doi-asserted-by":"crossref","DOI":"10.2196\/37487","article-title":"The Effectiveness of eHealth Interventions on Lifestyle Modification in Patients With Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-analysis","volume":"25","author":"Kwon","year":"2023","journal-title":"J Med Internet Res"},{"key":"2026010701052021000_12.1.e001670.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026010701052021000_12.1.e001670.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"2026010701052021000_12.1.e001670.22","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane Handbook for Systematic Reviews of Interventions 1st ed. Wiley, 2019.","DOI":"10.1002\/9781119536604"},{"key":"2026010701052021000_12.1.e001670.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026010701052021000_12.1.e001670.24","doi-asserted-by":"crossref","unstructured":"A C Sterne J , Savovi\u0107 J , Page MJ , et al . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366. doi:10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2026010701052021000_12.1.e001670.25","unstructured":"Meta-analytic procedures for social research, Available: https:\/\/dash.harvard.edu\/handle\/1\/38784661 [Accessed 27 Apr 2024]."},{"key":"2026010701052021000_12.1.e001670.26","first-page":"239","article-title":"The Effect of Follow up (Telenursing) on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial","volume":"4","author":"Fard","year":"2016","journal-title":"Int J Community Based Nurs Midwifery"},{"key":"2026010701052021000_12.1.e001670.27","doi-asserted-by":"crossref","DOI":"10.1038\/srep36783","article-title":"Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"6","author":"Dong","year":"2016","journal-title":"Sci Rep"},{"key":"2026010701052021000_12.1.e001670.28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/liv.13622","article-title":"Text messaging approach improves weight loss in patients with nonalcoholic fatty liver disease: A randomized study","volume":"38","author":"Axley","year":"2018","journal-title":"Liver Int"},{"key":"2026010701052021000_12.1.e001670.29","doi-asserted-by":"crossref","DOI":"10.2196\/14802","article-title":"Lifestyle Intervention Enabled by Mobile Technology on Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial","volume":"8","author":"Lim","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"2026010701052021000_12.1.e001670.30","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000052","article-title":"Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH","volume":"7","author":"Stine","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026010701052021000_12.1.e001670.31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/hep.32274","article-title":"NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH","volume":"76","author":"Stine","year":"2022","journal-title":"Hepatology"},{"key":"2026010701052021000_12.1.e001670.32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clnesp.2021.03.031","article-title":"Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial","volume":"43","author":"Policarpo","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"2026010701052021000_12.1.e001670.33","doi-asserted-by":"crossref","DOI":"10.2196\/49839","article-title":"Mobile App-Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial","volume":"26","author":"Kwon","year":"2024","journal-title":"J Med Internet Res"},{"key":"2026010701052021000_12.1.e001670.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-57722-7","article-title":"Implementation of a randomized mobile-technology lifestyle program in individuals with nonalcoholic fatty liver disease","volume":"14","author":"Tincopa","year":"2024","journal-title":"Sci Rep"},{"key":"2026010701052021000_12.1.e001670.35","doi-asserted-by":"crossref","DOI":"10.17533\/udea.iee.v36n3e09","article-title":"Effect of tele-nursing in the improving of the ultrasound findings in patients with nonalcoholic fatty liver diseases: A Randomized Clinical Trial study","volume":"36","author":"Ghodsbin","year":"2018","journal-title":"Invest Educ Enferm"},{"key":"2026010701052021000_12.1.e001670.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762"},{"key":"2026010701052021000_12.1.e001670.37","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.15227","article-title":"How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?","volume":"13","author":"Ghaemi","year":"2013","journal-title":"Hepat Mon"},{"key":"2026010701052021000_12.1.e001670.38","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.027581"},{"key":"2026010701052021000_12.1.e001670.39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/obr.12268","article-title":"eh ealth interventions for the prevention and treatment of overweight and obesity in adults: a systematic review with meta\u2010analysis","volume":"16","author":"Hutchesson","year":"2015","journal-title":"Obes Rev"},{"key":"2026010701052021000_12.1.e001670.40","unstructured":"Pfizer . NASH overview: causes, symptoms, diagnosis, and treatment. Pfizer; 2022. Available: https:\/\/www.pfizer.com\/disease-and-conditions\/nash [Accessed 8 Jun 2024]."},{"key":"2026010701052021000_12.1.e001670.41","unstructured":"Nonalcoholic Fatty Liver Disease Fibrosis Score: Uses and Results, Available: https:\/\/www.healthline.com\/health\/fatty-liver-score#interpreting-results"},{"key":"2026010701052021000_12.1.e001670.42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cpt.3009","article-title":"Design and Execution of Sustainable Decentralized Clinical Trials","volume":"114","author":"Singh","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2026010701052021000_12.1.e001670.43","doi-asserted-by":"crossref","unstructured":"Rao RKR . Leveraging Decentralized Clinical Trial Management Systems (dCTMS) to Advance Science: Exploring Challenges Related to the Diffusion of Innovation and Its Execution. Blockchain Healthc Today 2024;7. doi:10.30953\/bhty.v7.305","DOI":"10.30953\/bhty.v7.305"},{"key":"2026010701052021000_12.1.e001670.44","unstructured":"FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA; 2024. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease [Accessed 15 Mar 2024]."},{"key":"2026010701052021000_12.1.e001670.45","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S2589-7500(24)00174-2","article-title":"The new digital era in decompensated cirrhosis","volume":"7","author":"Gananandan","year":"2025","journal-title":"Lancet Digit Health"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2024-001670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:05:48Z","timestamp":1767776748000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2024-001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4,9]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjgast-2024-001670"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2024-001670","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}